132 related articles for article (PubMed ID: 36409433)
21. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX
Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446
[TBL] [Abstract][Full Text] [Related]
22. Single-cell characteristics and malignancy regulation of alpha-fetoprotein-producing gastric cancer.
Mei Y; Li M; Wen J; Kong X; Li J
Cancer Med; 2023 May; 12(10):12018-12033. PubMed ID: 37017469
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Ikeda M; Callies S; McGrath LM; Wang C; Abada P; Widau RC; Gonzalez-Gugel E; Zhu AX
Clin Cancer Res; 2022 Jun; 28(11):2297-2305. PubMed ID: 35247922
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological and molecular characteristics of the alpha-fetoprotein-producing gastric cancer: emphasis on two major subtypes.
Lu J; Jin M; Zhou X; Chen X; Shao Y; Jiang X
APMIS; 2022 Mar; 130(3):169-180. PubMed ID: 34862662
[TBL] [Abstract][Full Text] [Related]
25. Double cancer of the stomach, one AFP-producing tumor.
Hyodo T; Kawamoto R
J Gastroenterol; 1996 Dec; 31(6):851-4. PubMed ID: 9027651
[TBL] [Abstract][Full Text] [Related]
26. [Clinicopathologic features and prognosis of 51 patients with α-fetoprotein-producing gastric cancer].
Liu X; Yang M; Gao J; Zhang S; Xi Y
Zhonghua Zhong Liu Za Zhi; 2015 Mar; 37(3):231-4. PubMed ID: 25975796
[TBL] [Abstract][Full Text] [Related]
27. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Zhu AX; Finn RS; Kang YK; Yen CJ; Galle PR; Llovet JM; Assenat E; Brandi G; Motomura K; Ohno I; Daniele B; Vogel A; Yamashita T; Hsu CH; Gerken G; Bilbruck J; Hsu Y; Liang K; Widau RC; Wang C; Abada P; Kudo M
Br J Cancer; 2021 Apr; 124(8):1388-1397. PubMed ID: 33531690
[TBL] [Abstract][Full Text] [Related]
28. ANGPTL6-mediated angiogenesis promotes alpha fetoprotein-producing gastric cancer progression.
Chen E; Tang C; Peng K; Cheng X; Wei Y; Liu T
Pathol Res Pract; 2019 Aug; 215(8):152454. PubMed ID: 31146977
[TBL] [Abstract][Full Text] [Related]
29. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
30. Factors predictive of clinical outcome in advanced hepatocellular carcinoma patients receiving ramucirumab treatment: A real-world experience.
Lin PT; Hung MH; Shao SC; Chen HY; Chan YY; Chang KC; Lin SM; Ou HT
Cancer Med; 2023 Jul; 12(14):14902-14911. PubMed ID: 37278402
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic features of gastric cancers producing alpha-fetoprotein.
Kono K; Amemiya H; Sekikawa T; Iizuka H; Takahashi A; Fujii H; Matsumoto Y
Dig Surg; 2002; 19(5):359-65; discussion 365. PubMed ID: 12435906
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of Ramucirumab
Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
[TBL] [Abstract][Full Text] [Related]
33. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
[TBL] [Abstract][Full Text] [Related]
34. Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets.
Lu J; Ding Y; Chen Y; Jiang J; Chen Y; Huang Y; Wu M; Li C; Kong M; Zhao W; Wang H; Zhang J; Li Z; Lu Y; Yu X; Jin K; Zhou D; Zhou T; Teng F; Zhang H; Zhou Z; Wang H; Teng L
Nat Commun; 2021 Jun; 12(1):3946. PubMed ID: 34168152
[TBL] [Abstract][Full Text] [Related]
35. Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells.
Kamata S; Kishimoto T; Kobayashi S; Miyazaki M; Ishikura H
Cancer Biol Ther; 2007 Jul; 6(7):1036-43. PubMed ID: 17568186
[TBL] [Abstract][Full Text] [Related]
36. Predictive and prognostic value of serum AFP level and its dynamic changes in advanced gastric cancer patients with elevated serum AFP.
Wang YK; Shen L; Jiao X; Zhang XT
World J Gastroenterol; 2018 Jan; 24(2):266-273. PubMed ID: 29375212
[TBL] [Abstract][Full Text] [Related]
37. Alpha-fetoprotein is a significant prognostic factor for gastric cancer: Results from a propensity score matching analysis after curative resection.
Reim D; Choi YS; Yoon HM; Park B; Eom BW; Kook MC; Ryu KW; Choi IJ; Joo J; Kim YW
Eur J Surg Oncol; 2017 Aug; 43(8):1542-1549. PubMed ID: 28511775
[TBL] [Abstract][Full Text] [Related]
38. [AFP-producing gastric cancer and hepatoid gastric cancer].
Wang YK; Zhang XT
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):801-807. PubMed ID: 29151285
[TBL] [Abstract][Full Text] [Related]
39. Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Chau I; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Kudo M; Pfiffer T; Hatano E; Chung HC; Kopeckova K; Phelip JM; Brandi G; Ohkawa S; Li CP; Okusaka T; Hsu Y; Abada PB; Zhu AX
Br J Cancer; 2018 Jul; 119(1):19-26. PubMed ID: 29808014
[TBL] [Abstract][Full Text] [Related]
40. Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer.
Hirajima S; Komatsu S; Ichikawa D; Kubota T; Okamoto K; Shiozaki A; Fujiwara H; Konishi H; Ikoma H; Otsuji E
World J Gastroenterol; 2013 Sep; 19(36):6055-61. PubMed ID: 24106406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
